Anthracimycin
CAS: 1452849-94-3
Rif. 3D-CIC84994
| 1mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione |
Informazioni sul prodotto
Nome:
Anthracimycin
Sinonimi:
- (4R,7R,8E,10Z,12S,12aR,14aR,18aS,18bR)-7,12,12a,14a,15,18,18a,18b-Octahydro-4,7,12,16-tetramethyl-1H-naphth[1,2-g]oxacyclotetradecin-1,3,5(2H,4H)-dione
- N1097
- 1H-Naphth[1,2-g]oxacyclotetradecin-1,3,5(2H,4H)-dione, 7,12,12a,14a,15,18,18a,18b-octahydro-4,7,12,16-tetramethyl-, (4R,7R,8E,10Z,12S,12aR,14aR,18aS,18bR)-
Descrizione:
Anthracimycin is a potent anticancer agent that is derived from a marine bacterium. It targets the cell cycle of human tumor cells and induces apoptosis, which leads to cell death. Anthracimycin acts as an inhibitor of protein kinases, which are enzymes involved in many cellular processes including cell division and growth. This medicinal compound has been found to be effective against various types of cancer including breast, colon, and lung cancer. Chinese researchers have identified an analog of anthracimycin in human urine that may have potential as a novel cancer therapeutic agent. This inhibitor has shown promising results in preclinical studies and is currently being evaluated for its efficacy in clinical trials.
Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:
Proprietà chimiche
Peso molecolare:
396.5 g/mol
Formula:
C25H32O4
Purezza:
Min. 95%
MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:
